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Abstract
Group B Streptococcus (GBS) is the leading cause of meningitis in neonates. We have previously shown that plasminogen,
once recruited to the GBS cell surface and converted into plasmin by host-derived activators, leads to an enhancement of
bacterial virulence. Here, we investigated whether plasmin(ogen) bound at the GBS surface contributes to blood-brain
barrier penetration and invasion of the central nervous system. For that purpose, GBS strain NEM316 preincubated with or
without plasminogen plus tissue type plasminogen activator was analyzed for the capacity to adhere to, invade and
transmigrate the human brain microvascular endothelial cell (hBMEC) monolayer, and to penetrate the central nervous
system using a neonatal mouse model. At earlier times of infection, plasmin(ogen)-treated GBS exhibited a significant
increase in adherence to and invasion of hBMECs. Later, injury of hBMECs were observed with plasmin(ogen)-treated GBS
that displayed a plasmin-like activity. The same results were obtained when hBMECs were incubated with whole human
plasma and infected with untreated GBS. To confirm that the observed effects were due to the recruitment and activation of
plasminogen on GBS surface, the bacteria were first incubated with epsilon-aminocaproic acid (eACA), an inhibitor of
plasminogen binding, and thereafter with plasmin(ogen). A significant decrease in the hBMECs injury that was correlated
with a decrease of the GBS surface proteolytic activity was observed. Furthermore, plasmin(ogen)-treated GBS infected
more efficiently the brain of neonatal mice than the untreated bacteria, indicating that plasmin(ogen) bound to GBS surface
may facilitate the traversal of the blood-brain barrier. A higher survival rate was observed in offspring born from eACA-
treated mothers, compared to untreated mice, and no brain infection was detected in these neonates. Our findings suggest
that capture of the host plasmin(ogen) by the GBS surface promotes the crossing of the blood-brain barrier and contributes
to the establishment of meningitis.
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Introduction
Group B Streptococcus (GBS), a common designation for
Streptococcus agalactiae, is the leading cause of neonatal infectious
diseases comprising pneumonia, sepsis, and meningitis [1]. Despite
antibiotic therapy, the associated mortality remains high (approx-
imately 10%) and up to 50% of surviving infants experience
permanent neurological sequelae as deafness, seizures, hydro-
cephalous, cerebral palsy, and cognitive deficits [2,3,4]. How GBS
causes meningitis remains incompletely understood [5] and efforts
should be made to characterize the underlying pathogenic
mechanisms that are essential for crossing the blood – brain
barrier (BBB). The functional site of the BBB is the endothelial
lining of the brain capillaries constituted by microvascular
endothelial cells (BMECs). Blood-borne pathogens may enter the
central nervous system (CNS) through multiple mechanisms of
transmigration across the brain vasculature such as intercellular
(paracellular) and/or transcellular passage, disruption of the
endothelial barrier, and leukocyte-facilitated transport by infected
phagocytes (also named Trojan horse) [6,7]. GBS interaction with
hBMECs is the primary step in the pathogenesis of meningitis
where bacterial transcytosis, endothelial injury, and inflammatory
mechanisms may combine to disrupt the BBB [8].
It has been recognized that several human bacterial pathogens
gain a survival advantage by interacting with components of the
host plasminogen system [9,10]. Plasminogen is a central
component of the fibrinolytic system and is found in plasma and
extracellular fluids at concentrations of approximately 2 mM.
Upon activation, plasminogen is converted to the serine protease
plasmin that is able to degrade fibrin clots, connective tissue,
extracellular matrix (ECM), and adhesion proteins. However,
several pathogenic microbes manipulate the host plasminogen
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system to promote their dissemination across several host tissue
barriers [9,10,11,12] including the endothelium [13,14]. Acquisi-
tion of a surface-associated plasmin activity by a pathogen likely
increases its ability to penetrate the ECM and disseminate to distal
sites in the host, a process well documented in the case of
Streptococcus pyogenes [15,16], Borrelia burgdorferi [17,18], and Yersinia
pestis [12,19]. We have demonstrated that GBS can bind human
plasminogen and that this cell-surface associated proenzyme is
converted into plasmin by host-derived activators, a process
contributing to bacterial virulence [20]. Plasmin is a broad-specific
protease that can also activate other proteolytic enzymes such as
the matrix metalloprotease that degrades the tight junction
components of microvascular endothelial cells [9]. This destruc-
tion may favor the passage of bacteria across the vasculature of the
CNS and this scenario was proposed as the mechanism of
translocation of B. burgdorferi through the BBB [14]. We
hypothesized that modulation of the host plasminogen system by
GBS could play a role in the penetration of the BBB and
development of meningitis. In this study, we showed that the
presence of plasmin(ogen) on GBS cell surface increases its ability
to adhere to, invade, and traverse hBMECs, and enables a high
brain penetration in infected neonates. The bacterial invasiveness
was reduced following treatment with epsilon-aminocaproic acid
(eACA), a lysine analogue that efficiently inhibits the specific
binding of plasminogen to cells by competing with lysine-binding-
sites [21]. Moreover, addition of eACA to the drinking water of
mothers conferred protection to their progenies against GBS
infection. This study identifies the interaction of GBS with the host
plasminogen system as a key mechanism involved in the BBB
transmigration and subsequent CNS invasion. It opens new
avenues for the development of innovative strategies to prevent
bacterial invasion of the CNS.
Materials and Methods
Bacteria strain
Group B Streptococcus (GBS) serotype III virulent strain
NEM316 (serotype III, ST-23) was cultured at 37uC in Todd-
Hewitt (TH) broth or agar (Disco Laboratories) containing 5 mg/
mL of colistin sulphate and 0.5 mg/mL of oxalinic acid
(Streptococcus Selective Supplement, Oxoid).
Mice
Male and female BALB/c mice, purchased from Charles River
Laboratories (Barcelona, Spain), were bred at the animal facilities
of the ICBAS (Porto, Portugal).
Ethics statement
This study was carried out in strict accordance with the
recommendations of the European Convention for the Protection
of Vertebrate Animals used for Experimental and Other Scientific
Purposes (ETS 123) and 86/609/EEC Directive and Portuguese
rules (DL 129/92). The animal experimental protocol was
approved by the competent national authority Direcc¸a˜o Geral
de Veterina´ria (DGV) (Protocol Permit Number: 0420/000/000/
2008). All animal experiments were planned in order to minimize
mice suffering.
Culture of human endothelial cells
Human brain microvascular endothelial cell (hBMEC) line was
derived from primary cultures of hBMEC transfected with SV40
large T antigen [22] and was cultured as previously described [23].
Cell culture flasks or twenty-four well tissue culture plates were
precoated with rat tail collagen (BD Pharmingen) to support the
hBMEC monolayers. Viability of hBMEC was assessed by
examining cellular morphology and trypan blue exclusion.
Cultures were incubated at 37uC in a humid atmosphere of 5%
CO2 and split in 1:5 ratio by using trypsin-EDTA (Sigma-Aldrich)
when semiconuence was reached. HBMECs were transferred into
a collagen-coated 24-well tissue culture plate at a seeding density
of 105 cells in growth medium and left for at least 12 hours (h).
Prior to each assay, the monolayers were washed three times with
Hanks Balanced Salt Solution (HBSS) (Sigma-Aldrich).
Plasminogen binding and activation on GBS cell surface
Log-phase GBS cells were pelleted, washed three times in sterile
PBS, and approximately 26108 GBS cells were incubated for 1 h
at 37uC with 1 mg/mL of purified human plasminogen (Calbio-
chem) or human plasma. Thereafter, the bacteria were washed
with sterile PBS to remove unbound plasminogen and, when
incubated with purified plasminogen, tissue plasminogen activator
(tPA) (Sigma-Aldrich) was added (20 nM in PBS) for an additional
1 h to convert plasminogen into plasmin. In some experiments,
GBS cells were treated for 30 min at 37uC with 200 mM eACA
(Sigma-Aldrich) before incubation with plasminogen plus tPA to
inhibit GBS cell surface binding. The bacteria were then washed
three times in sterile PBS and resuspended at the desired density in
serum-deprived fresh cell culture medium without antibiotics.
Detection of plasminogen bound to GBS cell surface
Plasminogen conjugation with FITC was performed by
incubation for 1 h at 30uC in darkness of 400 mg of human
plasminogen with 40 mg of FITC (Sigma-Aldrich) in 500 mL of
1 M sodium carbonate buffer, pH 9.2. GBS cells were cultured to
log- phase, washed twice in PBS and then fixed in PBS containing
1% paraformaldehyde. After an incubation period of 20 min at
4uC, fixed bacteria were washed twice with PBS and incubated for
30 min at 37uC with different amounts of FITC-conjugated
human plasminogen (10, 20 and 50 mg) in 100 mL (final volume).
Thereafter, the cells were washed, resuspended in PBS, and
analyzed by fluorescence-activated cell sorter (FACS) on an Epics
XL cytometer (Beckman Coulter). Data were analyzed using the
Expo32 software.
Bacterial growth curves
Approximately 106 GBS cells, with or without pre-incubation
with human plasminogen plus tPA, or pre-incubated with human
plasma, were suspended in hBMEC growth medium without
antibiotics, and plated on a 24-well tissue culture plate. GBS cells
were quantified at different time intervals (15, 30, 45 minutes and
every hour up to 6 h) by platting appropriate dilutions of the
suspension onto agar plates.
Bacterial adherence and invasion assays in hBMECs
HBMECs invasion and adherence assays were performed as
previously described [24] with the following modifications.
HBMECs were infected with either 106 cells of plasmin(ogen)-
treated GBS, plasma-treated GBS or untreated GBS in 0.5 ml of
serum-deprived fresh cell culture medium without antibiotics to
give a multiplicity of infection (MOI) of 10 (10 bacteria per
hBMEC). In a separate experiment, hBMECs were incubated in
human plasma and infected with 106 cells of untreated GBS. The
cultures were maintained at 37uC in a humidified chamber
containing 5% CO2 and, at indicated time points, were washed
three times with HBSS to remove any nonadherent bacteria. For
invasion assays, the cultures were further incubated for additional
2 h at 37uC in 5% CO2 with 0.5 mL of hBMEC culture medium
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supplemented with antibiotics (penicillin 5 mg/ml and streptomy-
cin 100 mg/mL) to kill extracellular bacteria. After this incubation
period, the monolayers were washed with HBSS, 0.1 mL of
trypsin-EDTA solution was added, and the mixture was incubated
for 10 min at 37uC. Then, 0.4 mL of 0.025% Triton X-100 was
added and each hBMEC monolayer was disrupted by repeated
pipetting to release intracellular bacteria. For adhesion assay, total
hBMEC-associated (invasive plus surface adherent) GBS were
quantified as for the cellular invasion assay but the 2-h incubation
with antibiotics was omitted. The number of invasive and
adherent bacteria was determined by plating appropriate dilutions
of the lysate onto agar plates that were incubated overnight at
37uC. The number of adherent GBS to hBMECs was then
determined by subtracting the intracellular bacteria from the total
cell-associated (intracellular plus surface-adherent).
HBMEC injury assay
HBMECs were infected, as in the previous assay, with 106 cells
of plasmin(ogen)-treated or untreated GBS in 0.5 ml of serum-
deprived fresh cell culture medium without antibiotics to give a
MOI of 10. In a separate experiment, hBMECs were incubated in
human plasma and infected with 106 cells of untreated GBS. At
indicated time-points of infection, the cells were gently washed
with pre-warmed PBS. Adherent cells were dyed with Neutral Red
medium (40 mg/mL in complete medium) and incubated for
further 3 h at 37uC in a humidified chamber containing 5% CO2.
The medium was then carefully removed and the cells were
washed twice with pre-warmed PBS. The dye in each well was
extracted with de-staining solution (1% acetic acid/50% ethanol)
and the cells were allowed to stand for 10 min at room
temperature. The absorbance was read with a spectrophotometer
at a wavelength of 540 nm. The cell injury was evaluated by the
percentage of viability observed in infected cells relative to
uninfected cells. In some experiments, the hBMEC injury was
confirmed by measuring the release of lactate dehydrogenase
(LDH) into the supernatant of the hBMEC infected cells. In this
case, hBMECs were incubated with plasmin(ogen)-treated and
untreated GBS for 120 min, and the culture supernatant was
collected and centrifuged for 10 min at 12,000 g to remove the
cells. LDH activity was determined using a commercial kit (Sigma-
Aldrich) according to the manufacturer’s guidelines.
Migration assay of GBS across hBMEC
A endothelial BBB model in vitro was established by cultivating
the hBMECs on collagen-coated polycarbonate transwell mem-
brane inserts with a pore size of 3 mm (Corning). This in vitro
model of the BBB allows separate access to the upper chamber
(blood side) and lower chamber (brain side) and mimics GBS
penetration into the brain. The hBMEC monolayer was grown by
seeding 500 mL of growth medium containing 56105 cells in the
upper channel and 1,500 mL growth medium in the bottom
chamber of 12-well tissue culture inserts. The hBMEC were grown
to confluence for at least 5 days at 37uC in a humidified chamber
containing 5% CO2. At this point, the transendothelial electric
resistance (TEER) of this monolayer was around 200–250 V
cm22, as measured with a Millicell ERS-2 (Electrical Resistance
System) meter (Millipore). In our experiment, only monolayers
with TEER greater than 200 V cm22 were used. Prior to the
assay, hBMECs were washed and serum-free culture medium
without antibiotics was added. Log-phase GBS cells (106 CFU)
untreated or treated with human plasmin(ogen) were applied to
the apical chamber (total volume of 500 mL) and the monolayers
were incubated at 37uC in a humidified chamber containing 5%
CO2. At 1 and 2 h post-infection, the lower chamber medium was
entirely removed and plated onto TH agar to enumerate the
number of bacteria crossing the hBMEC monolayer. Simulta-
neously, the integrity of the hBMEC monolayer was assessed by
TEER measurement. Three measurements were made at each
time-point for every sample.
Determination of GBS cell surface plasmin-like activity
HBMECs cultured in 24-well plates were infected with 106 cells
of plasmin(ogen)-treated or untreated GBS resuspended in growth
medium, or with 106 cells of untreated GBS in whole human
plasma. In some experiments, GBS cells were incubated for 1 h at
37uC with 200 mM eACA before plasminogen and tPA treatment.
The cultures were incubated at 37uC in a humidified chamber
containing 5% CO2. At the desired time point post-infection, the
supernatant was removed and centrifuged for 10 min at 12,000 g
to recover GBS cells. The bacterial cells were then washed once in
PBS and resuspended in the chromogenic plasmin substrate Val-
Leu-Lys-p-nitroanilide (400 mM final concentration) (S2251,
Chromogenix). Following a 24 h incubation period at 37uC, the
cells were pelleted and the optical density of the supernatant was
read at 405 nm using a microplate reader. All samples were loaded
into triplicate wells. At each time-point, the bacterial growth in the
supernatant was also quantified by plating appropriate dilutions of
the supernatant onto TH agar plates.
Challenging infections of newborn mice
2-days old BALB/c mice were infected intraperitoneally (i.p.)
with 56106 cells of plasminogen-treated and untreated GBS in a
maximum volume of 40 mL. The brain of infected pups,
aseptically removed at indicated time points, was homogenized
in PBS and serial dilutions were plated on TH agar to enumerate
bacterial Colony-forming units (CFU). To inhibit plasminogen
binding to GBS, eACA was added (12 g/L) to the drinking water
of pregnant female BALB/c mice from the gestational day 15 to
the end of the experiment (sacrifice of the pups). As control
experiment, normal water was given to pregnant female. The
neonates were kept with their mothers throughout the end of the
experiments. Females were monitored closely during gestation and
the day of delivery was recorded. Two days after the birth, the
pups were infected with 56106 cells of untreated GBS and the
numbers of CFU in blood, liver, lung, and brain were determined
18 h post-infection. The organs aseptically removed at indicated
time points were homogenized in PBS and serial dilutions were
plated on TH agar to enumerate bacterial CFU. Survival curves
were determined in a 7-day experiment period.
Statistical analysis
All graphs were generated using GraphPad Prism software
(GraphPad Software). Means and standard errors of the means
(SEM) were calculated. Student’s t test was used to analyze the
differences between groups. Survival studies were analyzed with
the log-rank test. Both tests used GraphPad software. A P value of
,0.05 was considered statistically significant.
Results
Role of plasminogen system in adhesion and invasion of
the human brain endothelial cells by GBS
GBS adherence to BMECs constitutes the initial step in the
invasion into the CNS [24] and increased invasiveness is observed
when plasmin(ogen) is bound to GBS surface [20]. Therefore, we
set out to determine whether the plasminogen system plays a role
in the invasion of CNS by GBS. For that purpose, an hBMEC line
that maintains the morphological and functional properties of
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primary brain endothelium [25,26] was used to evaluate the
adhesion, invasion and injury of hBMECs after infection of GBS
preincubated with or without human plasminogen and tPA. We
first demonstrated that human plasminogen efficiently binds to
GBS cell surface (Figure 1A) and that the growth rates of the
plasmin(ogen)-treated and untreated GBS were identical
(Figure 1B). We next performed the adhesion and invasion assays
in hBMECs by plasmin(ogen)-treated or untreated GBS. At all
time points tested, a significant increase in the percentage of
bacterial cells adhered to endothelial cells was observed with
plasmin(ogen)-treated GBS, compared with untreated bacterium
(Figure 1C). Moreover, at 30 and 60 min post-infection, invasion
of hBMECs was only observed with plasmin(ogen)-treated bacteria
(Figure 1D) and, 90 min post-infection, the percent invasion was
significantly higher with plasmin(ogen)-treated GBS compared to
untreated bacteria. These results show that plasmin(ogen) bound
to GBS surface increase the ability of the bacterium to adhere to
and invade hBMECs.
Plasmin(ogen) bound to GBS surface induces hBMEC
injury
We have previously shown that plasminogen recruited to the
GBS cell surface by plasminogen receptors is converted into
plasmin by host-derived activators, thus generating a proteolytic
bacterium [20]. Therefore, we next questioned whether GBS
surface-bound plasmin(ogen) induced the hBMECs monolayer
disruption. The cell viability was assessed after infection of GBS
preincubated with or without plasminogen plus tPA. The
quantification of hBMECs viability, assessed 120 min post-
infection by the neutral red uptake assay, showed that the
percentage of viable hBMECs infected with untreated GBS was
greater than 95% (Figure 2A, lower left panel). In contrast, a
noticeable increase in hBMECs detachment was observed at
120 min post-infection with plasminogen-treated GBS that was
associated with a 50% decrease in hBMECs viability (P,0.0001).
However, when GBS cells were incubated with eACA before
plasminogen and tPA treatments only 20% of decrease in
hBMECs viability was observed (Figure 2A, lower left panel).
Moreover, the release of LDH by hBMECs was significantly
higher with plasmin(ogen)-treated GBS compared with untreated
bacteria (Figure 2A, lower right panel). Cell surface-bound plasmin is
exploited by bacteria for proteolytic degradation of components of
the ECM, basal membrane, and host tissues [27]. We therefore
determined the plasmin-like activity of GBS cell surface when
hBMECs were infected with plasmin(ogen)-treated or untreated
GBS. As shown in Figure 2B, the bacteria coated with
plasmin(ogen) displayed a significantly greater proteolytic activity
at the time point tested, which is abrogated when the GBS cells
were incubated with eACA before plasminogen and tPA
treatments. These results indicate that the cell surface-bound
plasmin(ogen) endows the bacteria with proteolytic activity that
promotes disruption of hBMECs monolayer.
Human plasma incubation increases the ability of GBS to
invade and degrade hBMECs
Numerous unrelated streptococcal surface proteins are involved
in the binding of plasminogen including the glycolytic enzymes
enolase, phosphoglycerate kinase, glyceraldehyde-3-phosphate
dehydrogenase (GAPDH), and phosphoglycerate mutase [28].
We have previously shown that plasma plasminogen is efficiently
recruited at the GBS cell surface [25] and, more recently, have
identified several plasminogen-binding receptors on the GBS
surface among which enolase and GAPDH were predominant in
binding plasminogen (Magalha˜es et al., unpublished data). To
provide a more physiologically relevant experimental set-up, the
invasion and hBMECs viability assays were studied following
incubation of the hBMECs monolayer in whole human plasma
that contains plasminogen at a physiological concentration (2 mM)
[29]. GBS invasion of the hBMECs was significantly greater at all
time points analyzed when the bacteria were pretreated with
human plasma compared to untreated cells (Figure 3A). This
difference was not due to increased bacterial growth since
untreated GBS or human plasma-treated GBS displayed similar
growth rates (data not shown). We next determined whether the
interaction of GBS with human plasma in the presence of
hBMECs can lead to acquisition of cell surface plasmin activity.
The proteolytic activity on the GBS cell surface was assessed using
the chromogenic substrate S2251 at different time points (60, 120,
180, 240, and 300 min) of co-culture. As shown in Figure 3B, GBS
co-cultured with hBMECs in human plasma acquired an
increasing surface plasmin-like activity over the incubation period
that reflects bacterial growth. To ensure that the observed GBS
cell surface plasmin activity was due to binding and activation of
the plasminogen present in human plasma, we determined at
300 min post-infection the proteolytic activity of GBS cells
previously incubated with eACA prior to hBMECs infection. As
shown in Figure 3C, pre-incubation of GBS with eACA
significantly (P=0.0231) inhibited the acquisition of cell surface
plasmin activity by GBS. The inhibition was not complete,
presumably because plasmin(ogen)-coated GBS can arise after
bacterial multiplication in the plasma. No difference between the
bacterial CFU at this time point was observed between eACA-
treated and untreated GBS indicating that the eACA treatment
did not modify the bacterial growth (data not shown). Moreover,
as shown in Figure 3D, infection of hBMECs with GBS in human
plasma leads to a significant cell detachment, as observed at 240
and 300 min post-infection. These experiments showed that
plasminogen present in plasma is recruited to the bacterial cell
surface and is converted into plasmin by host-derived activators
leading to hBMECs injury.
GBS-surface bound plasmin(ogen) promotes
transmigration across hBMECs
It was reported that GBS adheres to and invades hBMECs
[24], but the factors that contribute to the penetration of the
BBB remain to be characterized. To investigate the role of
plasminogen system in this process, an in vitro assay mimicking
GBS migration across the BBB was performed in a transwell
system. As shown in Figure 4, a time-dependent increase in GBS
crossing through the hBMECs monolayer was observed both
with untreated and plasmin(ogen)-treated bacteria. However,
plasmin(ogen) captured by the GBS cell surface significantly
increased the ability of this bacterium to traverse across the
hBMECs monolayer. After 60 and 120 min of infection,
plasmin(ogen)-treated bacteria displayed a 3- and 2-fold increase
in their ability to migrate through the hBMECs monolayer,
respectively, as compared to untreated GBS cells (Figure 4A).
Consistently, a significant reduction of the trans-epithelial electric
resistance (TEER) was observed when GBS cells were incubated
with plasmin(ogen), as compared to untreated bacteria, and this
effect was abolished by eACA (Fig. 4B). These results suggest that
the plasminogen system contributes to GBS migration across the
hBMEC monolayer by disrupting the cellular integrity.
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Role of the host plasminogen system in BBB penetration
in a murine model of infection
The in vitro results described above support our hypothesis that
interaction of GBS with the host plasminogen system enhances the
ability of this bacterium to invade the CNS in vivo. To confirm this
hypothesis, neonatal mice were infected by intraperitoneal route
(i.p.), 48 h after birth, with 56106 cells of plasmin(ogen)-treated or
untreated GBS. The bacterial load was determined at 6 h and
Figure 1. Plasmin(ogen)-coated GBS displays enhanced abilities to adhere to and invade hBMECs in vitro. (A) GBS cells were incubated
with FITC-labeled human plasminogen (hPLG) (grey filled histogram) or PBS (white dotted histogram). Plasminogen binding was measured by a
FACScan cytometer as the increase in FITC mean uorescent intensity (MFI). Each histogram shows cell number as a function of relative fluorescence
obtained for 10,000 events per population. Results are shown for 10, 20, and 50 mg of FITC-conjugated hPLG. (B) Representative growth curves of GBS
preincubated without (untreated GBS) or with (PLG-treated GBS) plasminogen plus tPA in complete hBMEC growth medium. Data are from a
experiment performed in triplicate that is representative of three independent experiments. Each point is the mean of three samples 6 SEM. (C and
D) HBMEC monolayers were infected with 106 cells of GBS preincubated without (untreated GBS) or with (PLG-treated GBS) plasminogen plus tPA
(MOI of 10 bacteria per cell). (C) HBMECs surface adherent GBS cells and (D) intracellular bacteria were isolated and enumerated after 30, 60, and
90 min of infection. The percentages of hBMECs surface adherent GBS and intracellular bacteria are expressed relative to the initial inoculums. Data
are the mean + SEM of three independent experiments. Statistical differences (P values) are indicated; ND – not detected.
doi:10.1371/journal.pone.0063244.g001
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18 h post-infection in the brains of the neonatal mice from both
groups. As shown in Figure 5A, 6 and 18 h after infection, the
brains of the neonates mice challenged with plasmin(ogen)-treated
GBS displayed higher bacterial counts than those challenged with
untreated GBS (P= 0.0450 and P= 0.0289, respectively). No
difference in bacterial counts was observed in the blood of pups
infected with untreated or plasmin(ogen)-treated GBS, excluding
Figure 2. Plasmin(ogen)-coated GBS induces hBMECs detachment and injury. GBS cells were preincubated without (untreated GBS) or with
(PLG-treated GBS) plasminogen plus tPA, or pre-treated with eACA prior to plasminogen plus tPA incubation (eACA-treated GBS). HBMECs
monolayers were infected with 106 CFU (MOI of 10) of untreated GBS, PLG-treated GBS or eACA-treated GBS, for 120 min at 37uC; uninfected cells
were used as negative controls. (A) Upper panel: representative microscopic photos of the average cell density were taken at6100 magnification for
visualization purposes. Lower left panel: percentage of viable cells, determined by the neutral red assay, expressed relative to the number of viable
cells observed in uninfected control. Lower right panel: Cell viability determined by measuring the LDH release. Data represents mean the values
normalized to the mean 100%-death control + SEM from an experiment performed in triplicate that is representative of three independent
experiments. (B) Plasmin-like activity in bacterial cell surface. The plasmin activity in GBS surface was assessed following incubation with its specific
chromogenic substrate S-2251 and determination of the absorbance at 405 nm. Data represents mean + SEM from an experiment performed in
triplicate that is representative of three independent experiments.
doi:10.1371/journal.pone.0063244.g002
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Figure 3. Incubation with human plasma increases the ability of GBS to invade and degrade hBMECs. (A) HBMECs monolayers were
infected with 106 GBS CFU (MOI of 10) pre-incubated or not with whole human plasma and bacterial invasion was determined at the indicated time
points and expressed in log 10 CFU/mL (left) or in percentage of intracellular bacteria relative to the initial inoculum. (B) HBMEC monolayer were
infected with 106 GBS CFU (MOI of 10) in whole human plasma and the plasmin-like activity of GBS cells was assessed as described in Figure 2C (bars
are the mean values of plasmin activity + SEM) and the bacterial CFU were determined at the same time points (line represents the mean numbers of
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the possibility that increased brain penetration was due to
increased levels of bacteremia (data not shown).
We further tested whether the increased entry of plasmin(ogen)-
treated GBS into the brain of infected pups was associated with
cell-surface plasmin(ogen) binding. Based on the knowledge that
orally administered eACA is almost entirely absorbed from the
gastrointestinal tract and is rapidly detected in plasma [30], we
developed an in vivo assay in which plasminogen binding to GBS
was blocked by adding eACA in the drinking water of pregnant
mice, while the control group was given normal water. Pups born
from eACA – treated or control females were infected i.p., 48 h
after birth with 56106 untreated-GBS cells. The pups were
maintained with their mothers throughout the experiments. Ten
out of the 12 mice born from eACA – treated mothers survived the
infection (83.3% survival) whereas all but two infected pups
succumbed to GBS challenge in the control group (16.7% survival)
(P= 0.0067) (Figure 5B). Moreover, as depicted in Figure 5C, a
significantly lower CFU of GBS were recovered 18 h after
infection from the liver of pups born from eACA–treated mothers,
as compared to the control group. Importantly, no bacterial counts
were detected 18 h after GBS infection in the lung and brain of
pups born from eACA – treated mothers (Figure 5C). Moreover,
in pups born from eACA-treated mothers, no CFU were detected
in all blood samples, while the blood samples of some control pups
were found to have CFU.
Altogether, our results indicate that interaction of GBS with the
host plasminogen system contributes to successful crossing of the
BBB and penetration into the CNS.
Discussion
A major limitation to advances in the prevention and treatment
of CNS infection is our incomplete understanding of the
pathogenesis of this disease and the associated BBB dysfunction.
The development of in vitro models of BBB crossing and in vivo
animal models of experimental haematogenous meningitis have
shed some light on the mechanisms of microbial traversal of the
BBB, the key step leading to CNS infections. Concerning the
pathophysiology of GBS, the precise mechanisms whereby this
bacterium leaves the bloodstream and access to the CNS remain
incompletely understood. A number of GBS surface proteins
including pili [31], the fibrinogen adhesin FbsA [32], the serine-
rich repeat glycoprotein Srr1 [33], the hypervirulent GBS adhesin
HvgA [6,34], the laminin-binding protein Lmb [35], and the
lipoteichoic acid anchoring enzyme LagA [36], have been shown
to promote in vitro adhesion to or invasion of BMECs. A recent
study identified the surface glycosaminoglycans as host receptor
molecules that interact with the GBS alpha C protein to facilitate
the bacterial entry into CNS [37].
We previously reported that GBS can specifically bind human
plasminogen that can be subsequently activated to plasmin by host
activators, such as uPA and tPA, and generate a proteolytic
bacterium that is more virulent [20]. As reported in other bacteria
[38,39] including streptococci [28] we have identified the GBS
enolase and GAPDH as predominant cell surface plasminogen
binding proteins (Magalha˜es et al., unpublished data). As these
proteins are essential for bacterial growth, the corresponding genes
could not be deleted. The ability of invasive pathogens to recruit
plasmin(ogen) on their surface constitutes a well described strategy
for translocation through tissue barriers and dissemination
bacterial CFU 6 SEM). (C) HBMECs monolayers were infected with 106 GBS CFU (MOI of 10) preincubated (GBS + eACA) or not (GBS) with 200 mM
eACA in whole human plasma for a 300 min period at 37uC. The acquisition of cell surface plasmin activity was detected as described in Figure 2C and
results are the mean values + SEM of the plasmin activity determined in one experiment performed in triplicate. These data are representative of
three independent experiments. Statistical differences (P values) are indicated. (D) Upper panel: representative microscopic photos of the average cell
density after 300 min of infection (for visualization purposes, magnification was at 100X). Bottom panel: the percentage of viable cells, assessed by the
neutral red assay, was determined as described in Figure 2A. Data are the mean + SEM and are representative of three independent experiments.
Statistical differences (P values) are indicated.
doi:10.1371/journal.pone.0063244.g003
Figure 4. Transmigration of GBS across hBMECs. (A) Confluent hBMECs monolayers grown in the upper chamber of Transwell inserts were
infected for a 2 h period with 106 GBS cells preincubated without (untreated GBS) or with (PLG-treated GBS) plasminogen plus tPA. The total lower
chamber medium was collected at the indicated time points and total GBS CFU were enumerated. (B) The integrity of the HBMEC monolayers
infected with 106 GBS CFU previously incubated with plasminogen plus tPA (PLG-treated GBS), untreated (untreated GBS) or pre-treated with eACA
prior to plasminogen plus tPA incubation (eACA-treated GBS) was monitored by measuring the change in TEER. Data are the mean values + SEM of at
least two experiments. Statistical differences (P values) are indicated.
doi:10.1371/journal.pone.0063244.g004
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[9,10,12,40]. In the present study, we demonstrated that GBS
utilizes the host plasminogen system to promote bacterial
migration across BBB and entry into the CNS. We showed that,
early after infection, GBS surface-bound plasmin(ogen) increased
the bacterial adherence to and invasion of hBMECs monolayer
and subsequently induced hBMECs injury and disruption by
endowing the bacteria with host-derived proteolytic activity.
Plasmin bound to GBS cell surface is enzymatically active, as
measured by the degradation of chromogenic specific plasmin
substrate. Several studies have shown that the acquired and
surface-bound proteolytic activity endows the bacterium with the
capacity to degrade components of the ECM [41] and penetrate
endothelial monolayers, including the BBB [13,14,42,43,44].
Accordingly, plasmin-mediated penetration of tissue barriers
leading to brain invasion was reported in the case of B. burgdorferi
[42]. Another important factor for the development of meningitis
Figure 5. Plasmin(ogen)-coated GBS displays enhanced abilities to invade the central nervous system. (A) Neonatal BALB/c mice were
infected i.p. at 48 h after birth with 56106 CFU of GBS incubated with (PLG-treated GBS) or without (untreated GBS) plasminogen plus tPA. GBS CFU
were determined in the brain of neonates at 6 and 18 h post-infection. Results from individual mice are shown. Statistical differences (P values)
between groups are indicated. (B and C) Pregnant BALB/c mice, from the gestational day 15 until the end of the experiment, were given drinking
water containing eACA (12 g/L) or normal water (control group). The newborns were kept with their mothers throughout the experiments. Two days
after the birth, the pups were infected with 56106 cells of untreated GBS. (B) Kaplan-Meier survival curves of neonatal mice born from eACA-treated
or control mothers. The numbers between parentheses represent the number of animals that survive versus the total number of infected animals.
Results represent data pooled from two independent experiments. (C) GBS CFU recovered at 18 h post-infection in the liver, lungs, blood and brain of
pups. Results from individual mice are shown. Statistical differences (P values) between groups are indicated. ND – not detected.
doi:10.1371/journal.pone.0063244.g005
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is the ability of pathogens to cross the BBB as live organisms.
Transmission electron microscopy studies with extracellular
pathogens (e.g., Escherichia coli and GBS) revealed that they
transmigrate across hBMECs monolayer in membrane-bound
enclosed vacuoles [24,45]. Our results suggest that these two
potential mechanisms can function sequentially. The increased
internalization detected early during the infection process should
favor the bacterial transcytosis, as reported by others [22,46], and
the cell injury and detachment of hBMECs observed later should
favor bacterial transmigration between injured cells. The loss of
BBB integrity had also been reported with the toxicity of bacterial
products and/or the activation of host inflammatory mediators
[47,48]. Here, we provide evidences that hijacking of the host
plasminogen system to generate a proteolytic bacterium constitutes
another mechanism enabling endothelial cell injury. Indeed, we
showed that incubation of hBMECs and GBS in human plasma
resulted in the acquisition of a plasmin activity at the bacterial
surface. This surface modification should facilitate the GBS
traversal of the extracellular matrix barriers and the tissue
penetration and, consequently, led to increased bacterial invasive-
ness. Our in vitro results were confirmed in vivo in a neonatal
murine model of GBS infection where an increased CNS
dissemination was observed in neonates infected with GBS cells
exhibiting surface-bound plasmin(ogen). This indicates that
recruitment of the host plasminogen to the bacterial surface
generates a proteolytic bacterium that, after conversion to plasmin,
possesses an increased ability to traverse the BBB. Since eACA has
been used as an anti-fibrinolytic agent in humans, this molecule
was added to the drinking water of mother’s mice. The liver of
GBS-infected pups born from eACA-treated mothers was much
less colonized than those born from untreated progenitors.
Remarkably, no bacterium was recovered from the lungs and
the brains of pups born from eACA-treated mothers, whereas
those of pups from untreated mothers were found to possess
detectable CFUs. Moreover, pups born from eACA-treated
mothers were free of detectable bacteremia which could indicate
that GBS-associated plasmin(ogen) facilitate bacterial access to the
vasculature with systemic spread, as described for Group A
Streptococcus [16]. Remarkably, the treatment of mothers with
eACA improved neonatal survival from 16.7 to 83.3%. Our results
combined with previous reports suggest that the ability to recruit
the host plasmin(ogen) could constitute a strategy utilized by
unrelated meningeal pathogens such as GBS (this work),
Streptococcus pneumoniae [49], and B. burgdorferi [13,14].
Overall, our findings suggest that plasmin(ogen) bound at GBS
surface facilitates bacterial penetration of CNS. To our knowledge,
this is the first report that identifies the interaction of GBS with the
host plasminogen system as one of the key events in the
pathogenesis of CNS infections. Moreover, our results suggest
that therapies aimed at neutralizing the activation of plasminogen
system at GBS surface could be beneficial in preventing
development of meningitis.
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